SEPN insider ownership: who sold, why, and what they still hold

What stands out

Outside holder RA CAPITAL MANAGEMENT, L.P., a 10% owner and not part of management, sold $63.5M of stock.Largest sale, Aug 12, 2026

A share of stake is shown for 0 of the 3 officers and directors who sold. 16 are left out

Left out: Jeffrey Finer, Elizabeth Bhatt, Uwe Klein, Alan Ezekowitz, Daniel Long, Gil Labrucherie, Abraham Bassan, Bernard Coulie, Jake Simson, Shalini Sharp, Samira Shaikhly, Jeffrey Tong, Jae Kim, Keith Gottesdiener, Mark Wilson and Rajiv Patni (share of stake is being verified).

Disclosed company stock is not an insider's whole wealth.

Who sold, and how much of their stake

Officers and directors, past 12 months. Their share of stake is being verified and is not shown yet; amounts and trading plans are below.

Samira Shaikhly

Chief People Officer

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$2.8MDisclosed plan

Elizabeth Bhatt

President and COO

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$1.4MDisclosed plan

Daniel Long

SVP, Drug Discovery

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$951K93% planned 7% no plan disclosed

Amounts, filings and trading plans for each seller

Selling by month

Officers and directors, Oct 2025 to Oct 2026. Each sale is counted once: under a disclosed plan, else to cover taxes, else no plan disclosed.

Disclosed planNo plan disclosedOne dollar scale for every month; the tallest bar is labeled

Recent activity

Past 30 days, Sep 14, 2026 to Oct 13, 2026

No officer or director trades were reported for the past 30 days. The most recent before that:

Sep 1, 2026Daniel Long sold 3.3K shares ($126K) under a disclosed trading plan. 3.3K shares came in from vesting or option exercises the same day, so the holding rose by 0 net.

Who	Shares	Price	% of total stake	Total stake after	Trade date	Filed
Daniel Long SVP, Drug Discovery	3,333	$37.83	n/a	n/a	Sep 1, 2026	Sep 3, 2026

Outside holders, reported separately

RA CAPITAL MANAGEMENT, L.P. sold $63.5M in the past 12 months. Large shareholders and the funds or companies that board members represent are not part of management, so they are left out of the figures above.

Details

Common questions

Is the Septerna, Inc. CEO selling stock?

No. Jeffrey Finer reported no open-market sales in the past 12 months.

Why are Septerna, Inc. insiders selling?

Filings rarely give a reason, and we don't guess at one. What they show is how the sales were made: 99% of sales by value ran under 10b5-1 trading plans disclosed in the filings and 1% had no disclosed plan. A trading plan schedules sales in advance.

Are any Septerna, Inc. insiders buying?

No. Officers and directors reported no purchases in the past 12 months.

The evidence

Who sold3 officers and directors: amount, % of holdings, trading plan

Who sold	Amount	% of holdings	Trading plan
Samira Shaikhly Chief People Officer	$2.8M 97K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
Elizabeth Bhatt President and COO	$1.4M 37K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
Daniel Long SVP, Drug Discovery	$951K 29K shares	Not confirmed share of stake is being verified. Why	93% under a disclosed plan 7% no plan disclosed

Outside holder, reported separately: Third Rock Ventures V, L.P. (a 10% owner, not part of management). No open-market sales reported in the period. Latest filing

Outside holder, reported separately: RA CAPITAL MANAGEMENT, L.P. (a 10% owner, not part of management). Sold $63.5M (1.49M shares) from Aug 12, 2026 to Aug 12, 2026. Latest filing

The full ownership picture0 of 16 officers and directors confirmed

Vested shares across all share classes, held directly and through trusts, LLCs and family members, as reported on SEC Forms 3, 4 and 5. Unvested awards and options are never counted as owned shares.

Insider

Held Oct 13, 2025

Sold

Held Oct 13, 2026

Still held

Jeffrey Finer

Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Jeffrey Finer are complete.

Chief Executive Officer, Director

n/a

Vesting, gifts, unvested awards and holding lines for Jeffrey Finer

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Jeffrey Finer are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
397,212	$2.76	Nov 11, 2033	$13.9M
301,475	$2.76	Mar 19, 2034	$10.6M
348,419	$6.81	Sep 22, 2034	$10.8M
210,000	$11.70	Aug 6, 2035	$5.5M
400,000	$25.41	Feb 5, 2036	$5.0M

Estimate: options held × ($37.83 − strike price), using the most recent insider trade price on Form 4 (Sep 1, 2026), not a market close.

Elizabeth Bhatt

President and COO

n/a

−37K

n/a

Vesting, gifts, unvested awards and holding lines for Elizabeth Bhatt

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Elizabeth Bhatt are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
82,332	$2.76	Nov 11, 2033	$2.9M
59,100	$2.76	Mar 19, 2034	$2.1M
62,230	$6.81	Sep 22, 2034	$1.9M
95,000	$11.70	Aug 6, 2035	$2.5M
155,000	$25.41	Feb 5, 2036	$1.9M

Estimate: options held × ($37.83 − strike price), using the most recent insider trade price on Form 4 (Sep 1, 2026), not a market close.

Uwe Klein

SVP, Biological Sciences

n/a

Vesting, gifts, unvested awards and holding lines for Uwe Klein

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Uwe Klein are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
10,453	$2.76	Nov 11, 2033	$367K
9,001	$2.76	Mar 19, 2034	$316K
33,027	$6.81	Sep 22, 2034	$1.0M
30,000	$11.70	Aug 6, 2025	$784K
80,000	$25.41	Feb 5, 2036	$993K

Estimate: options held × ($37.83 − strike price), using the most recent insider trade price on Form 4 (Sep 1, 2026), not a market close.

Alan Ezekowitz

Director

n/a

Vesting, gifts, unvested awards and holding lines for Alan Ezekowitz

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Alan Ezekowitz are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
11,613	$1.55	Dec 12, 2032	$421K
26,712	$2.76	Nov 11, 2033	$937K
23,227	$2.76	Mar 19, 2034	$815K
13,356	$6.81	Sep 22, 2034	$414K
16,623	$10.24	Jun 16, 2035	$459K
15,000	$37.34	Jun 25, 2036	$7K

Estimate: options held × ($37.83 − strike price), using the most recent insider trade price on Form 4 (Sep 1, 2026), not a market close.

Daniel Long

SVP, Drug Discovery

n/a

−29K

n/a

Vesting, gifts, unvested awards and holding lines for Daniel Long

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Daniel Long are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
5,227	$2.76	Nov 11, 2033	$183K
9,085	$2.76	Mar 19, 2034	$319K
40,648	$6.81	Sep 22, 2034	$1.3M
25,529	$11.70	Aug 6, 2035	$667K
80,000	$25.41	Feb 5, 2036	$993K

Estimate: options held × ($37.83 − strike price), using the most recent insider trade price on Form 4 (Sep 1, 2026), not a market close.

Gil Labrucherie

Chief Financial Officer

n/a

Vesting, gifts, unvested awards and holding lines for Gil Labrucherie

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Gil Labrucherie are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
222,000	$13.09	Feb 6, 2035	$5.5M
37,500	$11.70	Aug 6, 2035	$980K
125,000	$25.41	Feb 5, 2036	$1.6M

Estimate: options held × ($37.83 − strike price), using the most recent insider trade price on Form 4 (Sep 1, 2026), not a market close.

Abraham Bassan

Director

n/a

Vesting, gifts, unvested awards and holding lines for Abraham Bassan

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Abraham Bassan are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
13,356	$6.81	Sep 22, 2034	$414K
16,623	$10.24	Jun 16, 2035	$459K
15,000	$37.34	Jun 25, 2036	$7K

Estimate: options held × ($37.83 − strike price), using the most recent insider trade price on Form 4 (Sep 1, 2026), not a market close.

Bernard Coulie

Director

n/a

Vesting, gifts, unvested awards and holding lines for Bernard Coulie

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Bernard Coulie are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
29,034	$2.76	Dec 7, 2033	$1.0M
9,871	$2.76	Mar 19, 2034	$346K
13,356	$6.81	Sep 22, 2034	$414K
16,623	$10.24	Jun 16, 2035	$459K
15,000	$37.34	Jun 25, 2036	$7K

Estimate: options held × ($37.83 − strike price), using the most recent insider trade price on Form 4 (Sep 1, 2026), not a market close.

Jake Simson

Director

n/a

Vesting, gifts, unvested awards and holding lines for Jake Simson

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Jake Simson are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
13,356	$6.81	Sep 22, 2034	$414K
16,623	$10.24	Jun 16, 2035	$459K
15,000	$37.34	Jun 25, 2036	$7K

Estimate: options held × ($37.83 − strike price), using the most recent insider trade price on Form 4 (Sep 1, 2026), not a market close.

Shalini Sharp

Director

n/a

Vesting, gifts, unvested awards and holding lines for Shalini Sharp

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Shalini Sharp are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
29,034	$2.76	Jan 23, 2034	$1.0M
9,871	$2.76	Mar 19, 2034	$346K
13,356	$6.81	Sep 22, 2034	$414K
16,623	$10.24	Jun 16, 2035	$459K
15,000	$37.34	Jun 25, 2036	$7K

Estimate: options held × ($37.83 − strike price), using the most recent insider trade price on Form 4 (Sep 1, 2026), not a market close.

Samira Shaikhly

Chief People Officer

n/a

−97K

n/a

Vesting, gifts, unvested awards and holding lines for Samira Shaikhly

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Samira Shaikhly are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
11,614	$1.55	Mar 30, 2033	$421K
2,517	$2.76	Nov 11, 2033	$88K
4,464	$2.76	Mar 19, 2034	$157K
20,865	$6.81	Sep 22, 2034	$647K
23,750	$11.70	Aug 6, 2035	$621K
80,000	$25.41	Feb 5, 2036	$993K

Estimate: options held × ($37.83 − strike price), using the most recent insider trade price on Form 4 (Sep 1, 2026), not a market close.

Jeffrey Tong

Director

n/a

Vesting, gifts, unvested awards and holding lines for Jeffrey Tong

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Jeffrey Tong are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
13,356	$6.81	Sep 22, 2034	$414K
16,623	$10.24	Jun 16, 2035	$459K
15,000	$37.34	Jun 25, 2036	$7K

Estimate: options held × ($37.83 − strike price), using the most recent insider trade price on Form 4 (Sep 1, 2026), not a market close.

Jae Kim

Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Jae Kim are complete.

Chief Medical Officer

n/a

Vesting, gifts, unvested awards and holding lines for Jae Kim

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Jae Kim are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
185,823	$6.81	Sep 25, 2034	$5.8M
55,000	$11.70	Aug 6, 2035	$1.4M
125,000	$25.41	Feb 5, 2036	$1.6M

Estimate: options held × ($37.83 − strike price), using the most recent insider trade price on Form 4 (Sep 1, 2026), not a market close.

Keith Gottesdiener

Director

n/a

Vesting, gifts, unvested awards and holding lines for Keith Gottesdiener

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Keith Gottesdiener are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
33,246	$16.75	Sep 24, 2035	$701K
11,260	$37.34	Jun 25, 2036	$5K

Estimate: options held × ($37.83 − strike price), using the most recent insider trade price on Form 4 (Sep 1, 2026), not a market close.

Mark Wilson

Chief Legal Officer

n/a

Vesting, gifts, unvested awards and holding lines for Mark Wilson

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Mark Wilson are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
165,000	$25.41	Feb 5, 2036	$2.0M

Estimate: options held × ($37.83 − strike price), using the most recent insider trade price on Form 4 (Sep 1, 2026), not a market close.

Rajiv Patni

Chief Medical Officer

n/a

Vesting, gifts, unvested awards and holding lines for Rajiv Patni

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Rajiv Patni are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
275,000	$37.37	Sep 7, 2036	$126K

Estimate: options held × ($37.83 − strike price), using the most recent insider trade price on Form 4 (Sep 1, 2026), not a market close.

Holdings and share of stake for Septerna, Inc. are being verified, so no balances, unit counts or percentages are shown. Sales, proceeds, plan and tax status, titles and dates come straight from individual filings.

What explains the selling$5.2M of sales by plan status, purpose, seller and month

Officer and director open-market sales: $5.2M across 162,115 shares. Plan status and stated purpose are separate questions, and a sale can have both.

By plan status

Disclosed plan · $5.1M · 99%

The lighter segment is sales with no plan disclosed in the filing ($63K), including tax-related sales outside a plan.

No plan disclosed · $63K

Sales with no 10b5-1 plan and no tax reference in the filing. $63K of it is Daniel Long. No plan disclosed is a statement about the filing, not about why the sale happened. Largest such sale: Daniel Long, Nov 10, 2025

Seller	Shares sold	Proceeds	Under a disclosed plan	Share of total	Sales dates
Samira Shaikhly Chief People Officer	97K	$2.8M	100%	54%	Mar 2, 2026 to Jun 29, 2026
Elizabeth Bhatt President and COO	37K	$1.4M	100%	28%	Feb 18, 2026 to Aug 11, 2026
Daniel Long SVP, Drug Discovery	29K	$951K	93%	18%	Nov 10, 2025 to Sep 1, 2026

Sales by month

Month	Sale proceeds	Disclosed plan	To cover taxes	No plan disclosed
Oct 2025	$0	$0	$0	$0
Nov 2025	$63K	$0	$0	$63K
Dec 2025	$0	$0	$0	$0
Jan 2026	$0	$0	$0	$0
Feb 2026	$116K	$116K	$0	$0
Mar 2026	$2.0M	$2.0M	$0	$0
Apr 2026	$97K	$97K	$0	$0
May 2026	$355K	$355K	$0	$0
Jun 2026	$1.0M	$1.0M	$0	$0
Jul 2026	$251K	$251K	$0	$0
Aug 2026	$1.2M	$1.2M	$0	$0
Sep 2026	$126K	$126K	$0	$0
Oct 2026	$0	$0	$0	$0

Known gaps and uncertainty16 officers and directors not confirmed

Holdings and share of stake are being verified. Balances, unit counts and every share-of-stake figure for Septerna, Inc. are held back until that check is finished. Sales, proceeds, plan and tax status, titles and dates come straight from individual filings and are complete.

External context: we only cite outside events when a documented connection exists. None is shown for this period.

Sources and methodology79 filings on record, 35 filed in the 12-month period, and how we read them

All 79 Forms 3, 4 and 5 on record for Septerna, Inc. (SEC CIK 1984086), filed from Oct 24, 2024 to Sep 10, 2026; 35 of them were filed in the 12 months this page covers, retrieved from SEC EDGAR on Oct 13, 2026. Prices are the ones reported in each filing, often weighted averages.

Holdings. Each holding line (a share class plus an owner, such as a trust or LLC) carries its last reported balance forward. Entities first reported during the period start at zero, so transfers between an insider's own trusts don't count as selling. Lines not reported for three years or more are listed separately and left out of totals.

Sales. A sale counts as under a 10b5-1 plan if its footnote cites one or the filing's Rule 10b5-1 box is checked, and as tax-related if its footnote cites tax obligations or sell-to-cover. Shares withheld by the company for taxes are listed separately. Sales with neither attribute are labeled "no plan disclosed".

Full methodology

Former or inactive filers (1)No filing in 18 months; last reported balances, not in any total

Name	Last filed	Last reported balance
Ran Xiao	Oct 24, 2024	58,069 shares, last reported balance as of Oct 24, 2024

Spotted something wrong on this page? Report an error. We check every report against the SEC filing and list what we fix in the corrections log.

Septerna, Inc. insiders sold $5.2M in the past 12 months. How much of their stake is that?

What stands out

Who sold, and how much of their stake

Selling by month

Recent activity

Outside holders, reported separately

Common questions

Is the Septerna, Inc. CEO selling stock?

Why are Septerna, Inc. insiders selling?

Are any Septerna, Inc. insiders buying?

The evidence

No plan disclosed · $63K

Sales by month